1. Сметник В.П. Постменопаузальный остеопороз. Медицина климактерия. Ярославль: ООО "Изд-во Литтерра", 2006; 656–86.
2. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41.
3. Bishop NJ, Nincovic M, Alexander GJ et al. Changes in calcium homeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively. Clin Sci 1999; 97: 157–163.
4. Bonabello A, Galmozzi MR, Bruzzese T, Zara GP. Analgetic effect of biphosphonates in mice. Pain 2001; 91: 269–75.
5. Bone HG, Greenspan SL, McKeever C, Bell N et al. Alendronate and estrogen effects in postmenopausal women with low dose bone mineral density. J Clin Endocrinol Metab 2000; 85: 720–6.
6. Carr DB, Goudas LC. Acute pain. Lancet 1999; 353: 2051–8.
7. Cauley JA, Thompson DE, Ensrud KS et al. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556–61.
8. Cranney A, Wells G, Willan A et al. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570–8.
9. Center JR, Nguen TV, Schneider D et al. Mortality after all mayor types of osteoporetic fracture in men and women: an observational study. Lancet 1999; 353: 878–92.
10. Cummings SR, Melton LI. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761–7.
11. Downs JrRW, Bell NH, Ettinger MP et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000; 85: 1783–8.
12. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of biphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998; 78: 157–69.
13. Garnero P, Shih WJ, Gineyts E et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–700.
14. Geza B. Vizsgalatok a genericus alendronat natriummal, a Sedronnal. Praxis 2008; 17: 731–41.
15. Greenspan S, Field-Munves E, Tonino R et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002; 77: 1044–52.
16. Hodgson SF, Watts NB, Belezikian JP et al. American Assotiation of Clinical Endocrinologist medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544–64.
17. Hosking D, Chilvers CED, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338: 485–92.
18. Fleisch H. Biphosphonates: mechanism of action. Endocr Rev 1998; 19: 80–100.
19. Ismail AA, O`Neil TW, Cooper C et al. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 1998; 8: 291–7.
20. Javala T, Sama S, Pylkkanen L et al. Assotiation between vertebral fracture and increased mortality in osteoporetic patients. J Bone Miner Res 2003; 18: 1254–60.
21. Johnnel O, Oden A, Caulin F et al. Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 2001; 12: 207–14.
22. Johnell O, Kanis JA, Oden A et al. Mortality after osteoporotic fractures. Osteoporos Int 2004; 15: 38–42.
23. Kado DM, Browner WS, Palermo L et al. Vertebral fractures and mortality in older women: The Study of Osteoporotic Fractures. Arch Intern Med 1999; 159: 1215–20.
24. Kanis JA, Oden A, Johnell O et al. Excess mortality after hospitalization for vertebral fracture. Osteoporos Int 2004; 15: 108–12.
25. Kherani RB, Papaioannou A, Adachi JD. Long-term tolerability of the biphosphonates in postmenopausal osteoporosis: a comparative review. Drug Saf 2002; 25: 781–90.
26. Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 1995; 80: 3465–8.
27. Liberman UA, Weiss SR, Brоll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437–43.
28. Lindsay R, Silverman SL, Cooper C et al. Risk of a new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320–3.
29. Lips P. Invest in your bones: Quality of Life. Why prevent the first fracture? International Osteoporosis Foundation 2003.
30. Madhok R, Kerr H, Capell HA. Recent advances: rheumatology. BMJ 2000; 321: 882–5.
31. McClung M, Clemmesen B, Daifotis A et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind randomized, controlled trial. Ann Intern Med 1998; 128: 253–61.
32. Melton LJ, III. Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 2000; 15: 2309–14.
33. National Ostoporosis Foundation. Physician`s guide to prevention and treatment of osteoporosis. Belle Mead (NJ): Experta Medica; 1999.
34. National Ostoporosis Foundation 2004. Desease statistics.
35. Naves B, Diaz-Lopez JB, Gomez C et al. The effects of vertebral fracture and mortality in a Spanish population. Osteoporos Int 2003; 14: 520–4.
36. Norman P. Therapy markets and emerging technologies: Outlook for the osteoporosis market to 2005. Decision Resourses Inc 2001.
37. Opas EE, Rutledge SJ, Golub E et al. Alendronat ingibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol 1997; 54: 721–7.
38. Ott S. Osteoporosis and bone physiology. World Health Organizations definitions. http://www.uwcme.org/courses/bonephys/whodef.html.
39. Perez-Lopez FR. Postmenopausal osteoporosis and alendronate. Maturitas 2004; 48: 179–92.
40. Ravn P, Weiss S, Rodriguez-Portales JA et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 2000; 85: 1492–7.
41. Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in ageing men. J Bone Miner Res 1998; 13: 763–73.
42. Rizzoli R, Greenspan SL, Bone IIIG et al. Two years results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17: 1988–96.
43. Rossini M, Gatti D, Zamberlan N et al. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 1994; 9: 1833–7.
44. Russel RG, Rogers MG. Biphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97–106.
45. Santillan R, Hurle MA, Armijo JA et al. Nimodepine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: a double-blind, placebo-controlled study. Pain 1998; 76: 17–26.
46. Stone M. Once-weekly treatment for osteoporosis. Hosp Med 2002; 63: 230–2.
47. Wehren LE. The epidemiology of osteoporosis and fractures in geriatric medicine. Clin Geriatr Med 2003; 19: 245–58.
48. Writing group for the Women`s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women, JAMA 2002; 288: 321–33.

И.В.Кузнецова1, Ю.Б.Успенская2

1. Кафедра акушерства и гинекологии №1 лечебного факультета ММА им. И.М.Сеченова (зав. – проф. А.И.Ищенко), Москва
2. НИЦ ММА им. И.М.Сеченова